| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 659 | 5.866 | 13.514 | 6.516 | 7.992 |
| Total Income - EUR | - | - | - | - | - | 659 | 5.866 | 13.514 | 6.516 | 7.992 |
| Total Expenses - EUR | - | - | - | - | - | 2.144 | 7.627 | 16.125 | 15.628 | 10.081 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -1.485 | -1.761 | -2.611 | -9.113 | -2.088 |
| Net Profit/Loss - EUR | - | - | - | - | - | -1.485 | -1.761 | -2.842 | -9.143 | -2.088 |
| Employees | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Edopamine S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 0 | 0 | 0 | 608 |
| Current Assets | - | - | - | - | - | 764 | 6.080 | 2.092 | 6.418 | 4.488 |
| Inventories | - | - | - | - | - | 0 | 0 | 0 | 3.653 | 3.225 |
| Receivables | - | - | - | - | - | 0 | 2.896 | 81 | 0 | 271 |
| Cash | - | - | - | - | - | 764 | 3.184 | 2.011 | 2.765 | 991 |
| Shareholders Funds | - | - | - | - | - | -1.444 | -3.172 | -6.024 | -11.495 | -13.519 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 2.208 | 9.252 | 8.116 | 17.914 | 18.615 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4789 - 4789" | |||||||||
| CAEN Financial Year |
4789
|
|||||||||
Comments - Edopamine S.r.l.